Stocks · News reference

Sandoz Partners With Fresenius Unit mAbxience On Licensing, Development, Manufacturing And Commercialization For An Emicizumab Biosimilar Candidate

Sep 18, 2026, 10:23 AMBenzinga Newsdesk

Emicizumab biosimilar expands mAbxience's pipeline into haemophilia A and strengthens its presence in rare diseases.The agreement is consistent with mAbxience's strategy of broadening patient access to

More stocks news Connected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

FSNUY SDZNY

Source: benzinga
Observed: Sep 18, 2026, 10:23 AM
Checked: Sep 18, 2026, 10:23 AM
Cadence: Captured once, then retained as an archive reference
Status: fresh

Keep reading

Globenewswire IncJul 24, 2026, 2:46 PMResearchandmarkets.Com
Global Apheresis Market to Reach USD 4.41 Billion by 2031, Driven by Plasma-Based Therapies and Automated Technologies
The global apheresis market is projected to grow from USD 3.02 billion in 2026 to USD 4.41 billion by 2031, with a CAGR of 7.9%. Growth is driven by rising prevalence of autoimmune and neurological diseases, increased demand for plasma-derived therapies, and technological advances in automated systems. Disposables lead the product segment while plasmapheresis dominates procedures. North America holds the largest regional market share. Key challenges include high procedural costs and limited adoption in emerging markets.
HAE BDX FSNUY
BenzingaAug 17, 2026, 5:25 AMBenzinga Newsdesk
Henlius And Sandoz Enter Strategic Collaboration Covering Up To 10 Proposed Biosimilar Assets, Expanding Their 2025 Oncology Partnership
SDZNY SGBCF
BenzingaJul 22, 2026, 4:27 PMBenzinga Newsdesk
Shares of generic drug companies are trading lower after President Trump announced that imported generics will be subject to a 100% import tariff following a two-year grace period in order to encourage reshoring of pharma manufacturing.
AMPH AMRX ANIP SDZNY TEVA

Sandoz Partners With Fresenius Unit mAbxience On Licensing, Development, Manufacturing And Commercialization For An Emicizumab Biosimilar Candidate

Connected Markets

Related Headlines

Global Apheresis Market to Reach USD 4.41 Billion by 2031, Driven by Plasma-Based Therapies and Automated Technologies

Henlius And Sandoz Enter Strategic Collaboration Covering Up To 10 Proposed Biosimilar Assets, Expanding Their 2025 Oncology Partnership

Shares of generic drug companies are trading lower after President Trump announced that imported generics will be subject to a 100% import tariff following a two-year grace period in order to encourage reshoring of pharma manufacturing.